Charles River Laboratories International, Inc. (CRL)

From the record

Charles River Laboratories International, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Charles River Laboratories International, Inc.'s 10 filed years say what it did: revenue went from $1.7 billion in fiscal 2016 to $4.0 billion in fiscal 2025, up 10.2% a year; it rose in 7 of 9 years; the deepest fall was 3% from fiscal 2023 to fiscal 2025; net income was positive in 9 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-27, Charles River Laboratories International, Inc.'s diluted share count shrank about 1.1% a year, and dividends and buybacks returned about 23% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 21 sales (10 under scheduled 10b5-1 plans) and 2 purchases of their own stock on the open market in the year to 2026-11-09, buying about $7 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-27, Charles River Laboratories International, Inc. lost about 4 cents for every dollar of shareholders' money. Leverage: it owed about 56 cents per dollar of assets, and net share issuance: its share count shrank 4.0% over the year (the filed statements).

From the record

Charles River Laboratories International, Inc.'s standing among 12 graded names in its industry family: revenue of $4.0 billion in fiscal 2025 ranks in the top 29% by size; a net margin of -3.5% ranks in the top 46%; revenue growth of 0.3% a year over the last 3 filed years ranks in the bottom 46% (its annual reports).

From the record

Charles River Laboratories International, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Girshick, Birgit (Chief Executive Officer, as filed), filing under that title since 2026-05-28, 6 months (bottom 7% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 6.1 years (top 19%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (bottom 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Charles River Laboratories International, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $214 million against debt of $2.1 billion leaves -26.9% of its assets as net cash, bottom 21% of its family; cash from operations less capital spending is 12.9% of revenue (top 21%) (its annual report).

From the record

Charles River Laboratories International, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 0.3% a year over the last three filed years against 10.2% over all 10, slowing (bottom 29% of its family); the newest year grew -0.9% (top 46%); capital spending grew -12.3% a year (top 46%) (its annual reports). Charles River Laboratories International, Inc. reported 3 lines of business in fiscal 2025: Discovery and Safety Assessment at $2.4 billion (60%), Research Models and Services at $846 million (21%), Manufacturing Support at $766 million (19%); 1 of 3 grew against the year before (its annual report).

From the record

Charles River Laboratories International, Inc.'s newest year against its own record: revenue of $4.0 billion in fiscal 2025 came in 1.8% below the $4.1 billion its prior three years' pace pointed to (bottom 41% of its family); net income of $142 million against a prior three-year average of $333 million (bottom 5%); a net margin of -3.5% against 8.2% before (bottom 32%) (its annual reports).